Trial Profile
Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Euro-DIGNITY
- Sponsors Imunon
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 29 Mar 2022 Planned initiation date changed from 1 Aug 2017 to 1 Mar 2017.
- 29 Mar 2022 Status changed from suspended to withdrawn prior to enrolment.